SPA
BDTX icon

Sherbrooke Park Advisers’s Black Diamond Therapeutics BDTX Stock Holding History

Sherbrooke Park Advisers’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$29.3K Buy
+12,052
New +$42.7K 0.08% 181
2024
Q2 		– Sell
-10,912
Closed -$55.3K – 914
2024
Q1 		$55.3K Buy
+10,912
New +$44K 0.01% 816

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sherbrooke Park Advisers's BDTX Position: Q4 2025 in Review

Sherbrooke Park Advisers opened a new position in Black Diamond Therapeutics (BDTX) in Q4 2025: 12,052 shares worth $29.3K. The stake represents 0.08% of the portfolio and ranks #181 among its holdings. This is a return to the name: Sherbrooke Park Advisers previously reported a position in BDTX as recently as Q1 2024.

Sherbrooke Park Advisers first reported a position in BDTX in Q1 2024 and has held it in 2 quarters since. The position peaked at $55.3K in Q1 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q4 2025.

  • Sherbrooke Park Advisers held 12,052 shares of Black Diamond Therapeutics worth $29.3K as of Q4 2025.
  • Black Diamond Therapeutics was a new Sherbrooke Park Advisers position in Q4 2025.
  • Black Diamond Therapeutics made up 0.08% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #181 holding.
  • Sherbrooke Park Advisers first reported a position in Black Diamond Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • Sherbrooke Park Advisers's Black Diamond Therapeutics position peaked at $55.3K in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.